A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

This study is testing a new drug called Debio 1562M in people with acute myeloid leukemia (AML) — a fast-growing blood cancer — or with high-risk myelodysplastic syndrome (a condition where bone marrow doesn't make enough healthy blood cells), particularly when other treatments have stopped working. **You may be eligible if...** - You have been diagnosed with AML or high-risk MDS that has relapsed or is no longer responding to standard treatments - You are in generally good health despite your diagnosis - Your organ function (kidneys, liver, heart) meets the study's minimum requirements - You are willing to use effective contraception during and after the study **You may NOT be eligible if...** - You have a type of AML called acute promyelocytic leukemia (APL) - You have active, uncontrolled infection or severe organ failure - You have received certain prior therapies within specific timeframes - You are pregnant or breastfeeding - You have known HIV or active hepatitis B or C Talk to your doctor to see if this trial is right for you.